Accuray Incorporated (ARAY) announced late Friday a 10-year research collaboration with the University of Wisconsin School of Medicine and Public Health, centered on the company's Stellar adaptive radiotherapy platform. The announcement, made after the market close, follows a 5.2% decline in Accuray's share price to $0.27 during regular trading.
Partnership Details
The agreement aims to advance personalized cancer treatment through adaptive radiotherapy, a technique that adjusts radiation plans in real time as a patient's anatomy changes. The partnership will support clinical research, training, and the development of new adaptive therapies. Accuray CEO Steve La Neve stated that the deal formalizes and expands the company's existing work with UW-Madison, strengthening its connection to real-world clinical practice.
Background and Context
The collaboration has historical significance: UW-Madison professor Thomas "Rock" Mackie and his team developed technology in the late 1980s that later became Accuray's TomoTherapy system, the company's first helical radiation delivery platform. This deepens the relevance of the new agreement beyond a typical academic partnership.
Financial Pressures
Accuray's financial situation remains challenging. The company recently withdrew its fiscal 2026 guidance, citing Middle East shipment delays, weaker service revenue, and ongoing uncertainty in China. In the fiscal third quarter, net revenue fell 7% year-over-year to $104.8 million, with product revenue declining 13% and service revenue down 1%. The net loss widened to $11.8 million, or $0.09 per share. Gross product orders dropped to $48.5 million from $71.2 million a year earlier.
Analyst Reactions
Jefferies analyst Young Li downgraded Accuray from Buy to Hold, cutting the price target to $0.35, citing structural issues beyond the Q3 miss. BTIG also moved the stock to Neutral from Buy, pointing to continued pressure on product revenue from geopolitical risks and another adjusted EBITDA miss.
Competitive Landscape
Accuray faces strong competition in the adaptive radiotherapy space. Varian, now under Siemens Healthineers, offers the Ethos platform with AI-driven planning. Elekta provides a system combining CT and MR imaging with workflow support. Accuray's Stellar platform integrates image-guided radiation therapy with ClearRT helical kVCT imaging and an adaptive suite on the Radixact system.
Near-Term Risks
The research deal does not alleviate short-term pressures. Accuray reported $38.1 million in cash and cash equivalents as of March 31. Supply-chain and logistics costs are expected to weigh on cash flow from operations into fiscal 2026. Macroeconomic pressures could also affect covenant compliance. Additionally, Accuray faces a Nasdaq minimum bid requirement of $1.00, with a compliance deadline of August 3, 2026.
Outlook
While the UW agreement provides a compelling growth narrative in the adaptive cancer treatment market, execution remains the key challenge. Accuray must commercialize research, clear backlogged shipments, recover margins, and address its stock price, which closed just above its 52-week low ahead of the announcement.
